Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ITOS - ITeos Therapeutics Inc


IEX Last Trade
16.86
0   0%

Share volume: 410,491
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$16.86
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
12%
Profitability 10%
Dept financing 4%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-3.60%
1 Month
-3.55%
3 Months
-1.75%
6 Months
56.31%
1 Year
37.66%
2 Year
-24.78%
Key data
Stock price
$16.86
P/E Ratio 
-5.46
DAY RANGE
N/A - N/A
EPS 
-$3.15
52 WEEK RANGE
$8.20 - $18.75
52 WEEK CHANGE
$0.37
MARKET CAP 
615.393 M
YIELD 
N/A
SHARES OUTSTANDING 
36.522 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
0.85
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$242,191
AVERAGE 30 VOLUME 
$298,360
Company detail
CEO:
Region: US
Website: iteostherapeutics.com
Employees: 123
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

starting operations in 2012, iteos therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design. iteos is developing eos200271, a clinical-stage potent and selective ido1 inhibitor with exceptional brain penetration. the company is also advancing eos100850, an insurmountable and non-brain penetrant adenosine a2a receptor antagonist, into a phase 1 trial in the second half of 2018; and a human adcc-enabling anti-tigit antibody (eos884448), representing an additional, third clinical entry in 2019. based in gosselies, belgium, iteos therapeutics was founded and supported in part by investments from the ludwig institute cancer research (licr), the walloon region of belgium and the european fund for economic and regional development (feder). for more information, please visit www.iteostherapeutics.com.

Recent news